Postgraduate Institute of Medical Education and Research   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Chandigarh India (1962)

Organization Overview

First Clinical Trial
2004
NCT00375375
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Additional Professor, Division of Pediatric critical care, Dept of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, India | Aditya K Aggarwal | Assistant Professor, Division of Pediatric Critical care, Dept of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, India | Associate Professor, Department of Endocrinology, PGIMER Chandigarh India | Chief, Division of Pediatric Critical Care, Professor & Head, Department of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, India | Deepanjan Bhattacharya | Department of Endocrinology, PGIMER, Chnadigarh India | DM (Pediatric Critical Care) Senior Resident, Division of Pediatric critical care, Dept Of Pediatrics, Advanced Pediatrics Center, PGIMER, Chandigarh, INDIA | Dr. Ram Manohar Lohia Hospital and PGIMER | Dr. Ram Manohar Lohia Hospital, and Post Graduate Institute of Medical Education and Research | Dr. Ram Manohar Lohia Hospital & PGIMER | Institutional ethics committee,PGIMER Chandigarh,India | NAVNEH SAMAGH | PGI Hospital, Chandigarh, India | PGIMER Chandigarh | PGIMER,Chandigarh | PGIMER, Chandigarh | PGIMER CHANDIGARH | PGIMER, chandigarh, INDIA | PGIMER, Chandigarh,India | PGIMER, Chandigarh, India | PGIMER, CHANDIGARH, INDIA | PGIMER Dr. RML Hospital, Baba Kharak Singh Marg, Connaught Place, New Delhi- 110001, India | PIMER, Chandigarh | Post Grad Institute of Medical Education,& Research Dept of Neurology, Chandigarh | Postgraduate Institute for Medical Education & Research, Chandigarh, India | Postgraduate Institute of Medical and Research | Postgraduate Institute of Medical Education and Research | Post Graduate Institute of Medical Education and Research | Post Graduate Institute of Medical Education And Research | post graduate institute of medical education and research , chandigarh | Postgraduate Institute of Medical Education and Research, Chandigarh | Post Graduate Institute of Medical Education and Research, Chandigarh | Post Graduate Institute Of Medical Education And Research, Chandigarh | Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India | Postgraduate Institute of Medical Education and Research, Chandigarh-160012, India | Postgraduate Institute of Medical Education and Research Chandigarh India | Postgraduate Institute of Medical Education and Research, Chandigarh, India | Post Graduate Institute of Medical Education and Research; Chandigarh, India | Postgraduate Institute of Medical Education and Research,Department of Dermatology ,Venerology & Leprology,Sector-12-Chandigarh | Post graduate Institute of Medical Education & Research | Post Graduate Institute of Medical Education & Research | Post graduate institute of Medical Education & Research, Chandigarh, India | Post Graduate Institute of Medical Education & Research, Chandigarh, India | Postgraduate Institute of Medical Education & Research (PGIMER) | Professor, Department of Hepatology, PGIMER, Chandigarh | Professor of Hepatology,PGIMER,Chandigarh | Uprety Shraddha

Active Ingredients

Drugs in Phase 4 Trials (43)

acetylcysteine (mucomyst) (1 trial)

acitretin (soriatane) (1 trial)

apremilast (otezla) (1 trial)

atorvastatin (lipitor) (1 trial)

betamethasone (celestone) (1 trial)

bosentan (tracleer) (1 trial)

cefazolin (ancef) (1 trial)

desflurane (suprane) (4 trials)

dexmedetomidine (precedex) (5 trials)

folic acid (2 trials)

hsa-gcsf (1 trial)

insulin glargine (toujeo) (1 trial)

iron (2 trials)

isoflurane (forane) (1 trial)

itraconazole (sporanox) (7 trials)

ketamine (ketalar) (3 trials)

lactobacillus delbrueckii (2 trials)

lactulose (cephulac) (3 trials)

latanoprost (xalatan) (1 trial)

levobupivacaine (chirocaine) (5 trials)

linagliptin (tradjenta) (2 trials)

lipid emulsion (1 trial)

methotrexate (2 trials)

morphine (3 trials)

mycophenolate (myfortic) (2 trials)

naltrexone (revia) (2 trials)

nintedanib (ofev) (1 trial)

pioglitazone (actos) (3 trials)

pirfenidone (esbriet) (1 trial)

polyethylene glycol 3350 (colyte) (1 trial)

prednisolone (hydeltra) (5 trials)

propofol (diprivan) (9 trials)

rosuvastatin (crestor) (1 trial)

sargramostim (leukine) (3 trials)

sildenafil (viagra) (2 trials)

sitagliptin (januvia) (4 trials)

sodium chloride (7 trials)

somatropin (protropin) (2 trials)

terlipressin (3 trials)

tinefcon (1 trial)

urea (4 trials)

vitamin d3 (7 trials)

voglibose (1 trial)

Drugs in Phase 3 Trials (60)

acetaminophen (tylenol) (2 trials)

albumin (Human) (Plasbumin) (1 trial)

amphotericin b (fungizone) (3 trials)

atenolol (tenormin) (1 trial)

beractant (survanta) (1 trial)

bifidobacterium breve (1 trial)

bifidobacterium infantis (1 trial)

bifidobacterium longum (1 trial)

bovine colostrum (1 trial)

budesonide (rhinocort) (1 trial)

cadisurf (1 trial)

calcipotriene (dovonex) (1 trial)

cefixime (suprax) (1 trial)

ceftriaxone (rocephin) (2 trials)

ciprofloxacin (cipro) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

dapagliflozin (farxiga) (2 trials)

deflazacort (emflaza) (1 trial)

fentanyl (Innovar) (3 trials)

filgrastim (neupogen) (2 trials)

growth hormone (protropin) (2 trials)

hydroxychloroquine (plaquenil) (2 trials)

ibuprofen (motrin) (1 trial)

indomethacin (indocin) (2 trials)

Lactobacillus acidophilus (1 trial)

lactobacillus casei (1 trial)

lactobacillus plantarum (1 trial)

letrozole (femara) (1 trial)

lidocaine (xylocaine) (2 trials)

liraglutide (victoza) (1 trial)

meropenem (merrem) (1 trial)

methylprednisolone (medrol) (3 trials)

midazolam (versed) (1 trial)

midodrine (proamatine) (2 trials)

mononuclear cells (2 trials)

mycobacterium w vaccine (4 trials)

norepinephrine (levophed) (2 trials)

norfloxacin (noroxin) (1 trial)

platelets (1 trial)

prednisone (meticorten) (2 trials)

propranolol (inderal) (2 trials)

ramipril (altace) (1 trial)

rifaximin (xifaxan) (1 trial)

ringer's lactate (3 trials)

rituximab (rituxan) (1 trial)

ropivacaine (naropin) (2 trials)

safinamide (xadago) (1 trial)

simvastatin (zocor) (1 trial)

streptococcus salivarius (1 trial)

streptokinase (streptase) (1 trial)

sulbactam (unasyn) (1 trial)

tadalafil (cialis) (1 trial)

tamoxifen (nolvadex) (1 trial)

tar, coal (1 trial)

telmisartan (micardis) (1 trial)

tolvaptan (samsca) (1 trial)

tranexamic acid (cyklokapron) (3 trials)

voriconazole (vfend) (2 trials)

vsl #3 (1 trial)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 2 Trials (16)

aip-303 (1 trial)

allogeneic adipose derived mesenchymal stem cell (3 trials)

autologous mesenchymal stem cells (2 trials)

azathioprine (imuran) (1 trial)

bacille calmette-guerin (1 trial)

cisplatin (platinol) (1 trial)

cyclosporine (sandimmune) (2 trials)

docetaxel (taxotere) (1 trial)

immuvac (2 trials)

isotretinoin (accutane) (1 trial)

metoprolol (lopressor) (1 trial)

metronidazole (flagyl) (1 trial)

paclitaxel (taxol) (1 trial)

posaconazole (noxafil) (1 trial)

terbinafine (lamisil) (1 trial)

teriparatide (2 trials)

Drugs in Phase 1 Trials (2)

branched chain amino acids (1 trial)

diclofenac (voltaren) (1 trial)

Drugs in Other Trials (30)

acetazolamide (diamox) (1 trial)

albuterol (proventil) (1 trial)

aminophylline (aminophyllin) (1 trial)

attenuated measles vaccine (rubeovax) (1 trial)

b12 (1 trial)

cabergoline (dostinex) (1 trial)

carvedilol (coreg) (1 trial)

daclatasvir (daklinza) (2 trials)

epinephrine (levophed) (1 trial)

exenatide (byetta) (1 trial)

gurmar (1 trial)

honey (1 trial)

human fecal microbiota (Reybota) (2 trials)

insulin human (humulin) (1 trial)

iodized salt (1 trial)

ipratropium (atrovent) (1 trial)

isoniazid (nydrazid) (1 trial)

ivabradine (corlanor) (1 trial)

lactoferrin (1 trial)

ledipasvir (Harvoni) (1 trial)

magnesium sulfate (Tis-U-Sol) (1 trial)

oxygen (1 trial)

oxytocin (syntocinon) (1 trial)

platelet rich plasma (2 trials)

Rho(D) Immune Globulin Intravenous (Human) (WinRho) (1 trial)

ribavirin (virazole) (1 trial)

rifampin (1 trial)

sofosbuvir (sovaldi) (1 trial)

tazarotene (tazorac) (1 trial)

tofacitinib (xeljanz) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Abscess (Phase 3)

Acute-On-Chronic Liver Failure (Phase 4)

Alopecia (Phase 4)

Alopecia Areata (Phase 4)

Anemia, Iron-Deficiency (Phase 4)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Arthropathy, Neurogenic (Phase 3)

Ascites (Phase 3)

Aspergillosis (Phase 4)

Aspergillosis, Allergic Bronchopulmonary (Phase 3)

Brain Diseases (Phase 4)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Cataract (Phase 4)

Cerebral Infarction (Phase 1)

Colitis (Phase 4)

Colitis, Ulcerative (Phase 4)

Communicable Diseases (Phase 3)

Delirium (Phase 4)

Diabetes Complications (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Foot (Phase 4)

Diabetic Nephropathies (Phase 3)

Ductus Arteriosus, Patent (Phase 3)

Dwarfism (Phase 4)

Dyslipidemias (Phase 3)

Edema (Phase 4)

Empyema (Phase 4)

End Stage Liver Disease (Phase 4)

Familial Primary Pulmonary Hypertension (Phase 4)

Fibrosis (Phase 3)

Foot Ulcer (Phase 4)

Ganglion Cysts (Phase 3)

Glucose Intolerance (Phase 4)

Headache (Phase 2)

Heart Failure (Phase 2)

Heart Failure, Diastolic (Phase 2)

Heart Septal Defects (Phase 4)

Heart Septal Defects, Atrial (Phase 4)

Heart Valve Diseases (Phase 4)

Hemangioma (Phase 3)

Hemangioma, Capillary (Phase 3)

Hemoptysis (Phase 3)

Hemorrhage (Phase 4)

Hepatic Encephalopathy (Phase 4)

Hepatic Insufficiency (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis, Alcoholic (Phase 4)

Hepatorenal Syndrome (Phase 3)

Hypersensitivity (Phase 4)

Hypertension (Phase 4)

Infarction (Phase 1)

Infarction, Middle Cerebral Artery (Phase 1)

Infections (Phase 3)

Inflammatory Bowel Diseases (Phase 2)

Insulin Resistance (Phase 4)

Ischemia (Phase 1)

Joint Diseases (Phase 3)

Kidney Diseases (Phase 3)

Leukemia (Phase 4)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 4)

Leukemia, Myeloid (Phase 4)

Liver Abscess (Phase 3)

Liver Cirrhosis (Phase 3)

Liver Diseases (Phase 3)

Liver Failure (Phase 4)

Lung Diseases (Phase 3)

Lung Diseases, Interstitial (Phase 3)

Lung Neoplasms (Phase 2)

Macular Edema (Phase 4)

Mucormycosis (Phase 2)

Mycobacterium Infections (Phase 2)

Necrosis (Phase 3)

Obesity (Phase 3)

Organophosphate Poisoning (Phase 4)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Pancreatitis (Phase 3)

Paralysis (Phase 1)

Parkinson Disease (Phase 3)

Pemphigus (Phase 3)

Pleural Effusion (Phase 4)

Pleurisy (Phase 4)

Poisoning (Phase 4)

Port-Wine Stain (Phase 3)

Prediabetic State (Phase 4)

Prostatic Neoplasms (Phase 2)

Psoriasis (Phase 4)

Pulmonary Aspergillosis (Phase 4)

Pulmonary Valve Insufficiency (Phase 1)

Pyelonephritis (Phase 3)

Raynaud Disease (Phase 3)

Recurrence (Phase 2)

Respiratory Aspiration (Phase 4)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Respiratory Insufficiency (Phase 1)

Sarcoidosis (Phase 4)

Scleroderma, Diffuse (Phase 4)

Scleroderma, Localized (Phase 3)

Scleroderma, Systemic (Phase 4)

Sclerosis (Phase 4)

Sepsis (Phase 3)

Shock, Septic (Phase 3)

Stroke (Phase 2)

Subarachnoid Hemorrhage (Phase 4)

Syndrome (Phase 3)

Thoracic Diseases (Phase 4)

Tinea (Phase 2)

Toxemia (Phase 3)

Tuberculosis (Phase 3)

Ulcer (Phase 4)

Urinary Tract Infections (Phase 3)

Urticaria (Phase 4)

Vasoplegia (Phase 1)

Vasospasm, Intracranial (Phase 1)

Ventricular Dysfunction (Phase 4)

Ventricular Dysfunction, Right (Phase 4)

Vision Disorders (Phase 4)

Vitamin D Deficiency (Phase 4)

Weight Loss (Phase 3)

Zygomycosis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 162
  • # of Trial APIs: 151